Stocktoria
VERACYTE, INC. VCYT
Nasdaq · XNAS · stock · Services-Medical Laboratories · website · IPO 2013-10-30
VERACYTE, INC. financials (annual, from 10-K)
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | $517.1M | $445.8M | $361.1M | $296.5M | $219.5M |
| Gross profit | $362.5M | $298.1M | $229.7M | $175.7M | — |
| R&D expense | $70.8M | $69.3M | $57.3M | $40.6M | $29.8M |
| Operating income | $57.8M | $16.1M | -$85.8M | -$41.1M | -$81.9M |
| Income tax | $1.8M | $1.6M | -$2.2M | $133,000 | -$6.1M |
| Net income | $66.4M | $24.1M | -$74.4M | -$36.6M | -$75.6M |
| EPS (diluted) | $0.82 | $0.31 | $-1.02 | $-0.51 | $-1.11 |
| Operating cash flow | $136.3M | $75.1M | $44.2M | $7.5M | -$31.6M |
| Free cash flow | $126.6M | $63.8M | $34.3M | -$1.0M | -$37.0M |
| Cash & equivalents | $362.6M | $239.1M | $216.5M | $154.2M | $173.2M |
| Inventory | $20.5M | $21.8M | $16.1M | $14.3M | $11.2M |
| Total assets | $1.4B | $1.3B | $1.1B | $1.2B | $1.2B |
| Total liabilities | $96.4M | $124.1M | $70.8M | $81.2M | $91.3M |
| Shareholders' equity | $1.3B | $1.2B | $1.0B | $1.1B | $1.1B |
Source: SEC EDGAR filings · CIK 0001384101 · as of 2025-12-31. Facts from filings plus Stocktoria's own computed scores — not investment advice.